Form 4: Halozyme Director Sells Shares Under 10b5-1 Plan

Halozyme Therapeutics Director Bernadette Connaughton has sold a total of 1,625 shares of common stock under a pre-arranged trading plan.

Summary

• Bernadette Connaughton, a Director at Halozyme Therapeutics, Inc. (HALO), executed a sale of 1,625 shares of common stock on July 1, 2026.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on May 29, 2025, which is designed to comply with affirmative defense conditions for insider trading.
• A portion of the shares (1,000) were sold at a weighted average price of $76.395, with individual sales ranging from $75.930 to $76.850.
• An additional 625 shares were sold at a weighted average price of $77.209, with individual sales ranging from $76.950 to $77.710.
• Following these transactions, Connaughton beneficially owns 42,044 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider sales can be a negative signal, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating adherence to pre-determined trading strategies and regulatory compliance.
• The sales occurred at prices within a defined range, suggesting a structured and controlled divestment.

Negatives

• A director has sold a portion of their holdings, which could be perceived negatively by the market, although conducted under a plan.

Risks

• The sales, even under a 10b5-1 plan, could be interpreted by the market as a signal of reduced confidence by the director in the company's future stock performance.
• The specific reasons for the sale are not detailed beyond the existence of the trading plan, leaving room for speculation.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings reporting insider transactions are common and closely watched by investors. The use of a Rule 10b5-1 plan is a standard practice for executives to diversify their holdings or manage personal finances while mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders may view the director's sale with caution, although the 10b5-1 plan provides a degree of reassurance regarding compliance.
• The company's management team continues to operate under established governance protocols for insider trading.

Next Steps

• The reporting person will continue to adhere to the terms of the Rule 10b5-1 trading plan.
• Information regarding specific sale prices will be provided to the issuer, security holders, or SEC staff upon request.

Key Dates

Keywords

Halozyme Therapeutics, HALO, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Director Transaction, Beneficial Ownership, Securities Exchange Act